These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26681315)

  • 1. Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.
    Vivot A; Li J; Zeitoun JD; Mourah S; Crequit P; Ravaud P; Porcher R
    Genet Med; 2016 Aug; 18(8):796-805. PubMed ID: 26681315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
    Vivot A; Boutron I; Ravaud P; Porcher R
    Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
    Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
    Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.
    Vivot A; Boutron I; Béraud-Chaulet G; Zeitoun JD; Ravaud P; Porcher R
    Sci Rep; 2017 Jul; 7(1):6882. PubMed ID: 28761069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.
    Gershkovich P; Platt J; Knopf J; Tasoulis MK; Shi W; Pusztai L; Hatzis C
    JCO Clin Cancer Inform; 2018 Dec; 2():1-13. PubMed ID: 30652574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
    Parker JL; Kuzulugil SS; Pereverzev K; Mac S; Lopes G; Shah Z; Weerasinghe A; Rubinger D; Falconi A; Bener A; Caglayan B; Tangri R; Mitsakakis N
    Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
    Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
    Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
    Marquart J; Chen EY; Prasad V
    JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
    O'Donnell PH; Stadler WM
    Clin Cancer Res; 2012 May; 18(10):2809-16. PubMed ID: 22427349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A; Lopes G; Parker JL
    J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating many treatments and biomarkers in oncology: a new design.
    Kaplan R; Maughan T; Crook A; Fisher D; Wilson R; Brown L; Parmar M
    J Clin Oncol; 2013 Dec; 31(36):4562-8. PubMed ID: 24248692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
    Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.